Brown P, Cervenáková L, McShane L M, Barber P, Rubenstein R, Drohan W N
Laboratory of CNS Studies, National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-4122, USA.
Transfusion. 1999 Nov-Dec;39(11-12):1169-78. doi: 10.1046/j.1537-2995.1999.39111169.x.
Solid evidence from experimentally infected animals and fragmentary evidence from naturally infected humans indicate that blood may contain low levels of the infectious agent of Creutzfeldt-Jakob disease (CJD), yet blood components have never been identified as a cause of CJD in humans.
Blood components and plasma fractions were prepared from the pooled blood of mice that had earlier been infected with a mouse-adapted strain of human transmissible spongiform encephalopathy (TSE). Infectivity bioassays were conducted in healthy mice, and the brains of all assay animals dying during the course of the experiments were examined for the presence of proteinase-resistant protein.
Infectivity in the blood during the preclinical phase of disease occurred in the buffy coat at infectious unit (IU) levels between 6 and 12 per mL and was either absent or present in only trace amounts in plasma and plasma fractions. Infectivity rose sharply at the onset of clinical signs to levels of approximately 100 IU per mL of buffy coat, 20 IU per mL of plasma, 2 IU per mL of cryoprecipitate, and less than 1 IU per mL of fractions IV and V. Plasma infectivity was not eliminated by either white cell-reduction filtration or high-speed centrifugation. Approximately seven times more plasma and five times more buffy coat were needed to transmit disease by the intravenous route than by the intracerebral route.
Epidemiologic evidence of the absence in humans of disease transmission from plasma components can probably be explained by 1) the absence of significant plasma infectivity until the onset of symptomatic disease, and comparatively low levels of infectivity during the symptomatic stage of disease; 2) the reduction of infectivity during plasma processing; and 3) the need for at least five to seven times more infectious agent to transmit disease by the intravenous than intracerebral route. These and other factors probably also account for the absence of transmission after the administration of whole blood or blood components.
来自实验感染动物的确凿证据以及来自自然感染人类的零散证据表明,血液中可能含有低水平的克雅氏病(CJD)感染因子,但血液成分从未被确定为人类CJD的病因。
从先前感染了适应小鼠的人类传染性海绵状脑病(TSE)毒株的小鼠混合血液中制备血液成分和血浆组分。在健康小鼠中进行感染性生物测定,并检查所有在实验过程中死亡的测定动物的大脑中是否存在蛋白酶抗性蛋白。
在疾病临床前期,血液中的感染性存在于血沉棕黄层中,感染单位(IU)水平为每毫升6至12个,而血浆和血浆组分中要么不存在感染性,要么仅存在微量感染性。在临床症状出现时,感染性急剧上升,血沉棕黄层中达到约每毫升100 IU,血浆中为每毫升20 IU,冷沉淀中为每毫升2 IU,IV和V组分中每毫升低于1 IU。白细胞去除过滤或高速离心均未消除血浆感染性。通过静脉途径传播疾病所需的血浆量约为脑内途径的七倍,血沉棕黄层量约为五倍。
人类中缺乏血浆成分传播疾病的流行病学证据,可能可以解释为:1)在症状性疾病发作之前不存在显著的血浆感染性,且在疾病症状期感染性水平相对较低;2)血浆处理过程中感染性降低;3)通过静脉途径传播疾病所需的感染因子至少是脑内途径的五到七倍。这些因素以及其他因素可能也解释了输注全血或血液成分后未发生传播的原因。